COLL Collegium Pharmaceutical, Inc.
Stock · NasdaqGS · United States · Healthcare · US19459J1043
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Collegium Pharmaceutical, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:53. Information, not advice.
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 08:00 | 1.98 | — | — | Upcoming |
| 05 Nov 2026 07:00 | 1.86 | 1.96 | +5.6% | Beat |
| 06 Aug 2026 07:00 | 1.77 | 1.92 | +8.8% | Beat |
| 07 May 2026 07:00 | 1.52 | 1.76 | +15.5% | Beat |
| 26 Feb 2026 07:00 | 2.14 | 2.04 | -4.7% | Miss |
| 06 Nov 2025 07:00 | 1.86 | 2.25 | +21.0% | Beat |
| 07 Aug 2025 07:00 | 1.85 | 1.68 | -9.2% | Miss |
| 08 May 2025 16:00 | 1.45 | 1.49 | +2.8% | Beat |
| 27 Feb 2025 16:00 | 1.54 | 1.77 | +15.1% | Beat |
| 07 Nov 2024 16:00 | 1.59 | 1.61 | +1.1% | Beat |
| 08 Aug 2024 16:00 | 1.49 | 1.62 | +9.0% | Beat |
| 09 May 2024 16:00 | 1.47 | 1.45 | -1.4% | Miss |
| 22 Feb 2024 16:00 | 1.25 | 1.58 | +25.9% | Beat |
| 07 Nov 2023 16:00 | 1.24 | 1.34 | +8.3% | Beat |
| 03 Aug 2023 16:00 | 1.22 | 1.26 | +3.5% | Beat |
| 04 May 2023 16:00 | 1.51 | 1.32 | -12.8% | Miss |
| 23 Feb 2023 16:00 | 1.26 | 1.09 | -13.7% | Miss |
| 03 Nov 2022 16:00 | 1.38 | 1.10 | -20.4% | Miss |
| 04 Aug 2022 16:00 | 1.44 | 1.21 | -15.8% | Miss |
| 10 May 2022 16:00 | 0.90 | 0.91 | +1.2% | Beat |
| 24 Feb 2022 16:00 | 1.04 | -0.18 | -117.5% | Miss |
| 04 Nov 2021 16:00 | 0.96 | 0.78 | -18.4% | Miss |
| 05 Aug 2021 16:00 | 0.95 | 0.81 | -14.8% | Miss |
| 06 May 2021 16:00 | 1.00 | 0.96 | -4.8% | Miss |
| 25 Feb 2021 16:00 | 0.97 | 0.93 | -4.1% | Miss |
| 05 Nov 2020 16:00 | 0.90 | 1.03 | +14.5% | Beat |
| 05 Aug 2020 16:00 | 0.86 | 0.95 | +10.2% | Beat |
| 07 May 2020 17:00 | 0.66 | 0.89 | +34.7% | Beat |
| 27 Feb 2020 16:00 | 0.10 | 0.16 | +57.1% | Beat |
| 06 Nov 2019 16:00 | 0.03 | 0.05 | +81.1% | Beat |
| 07 Aug 2019 16:00 | -0.04 | 0.09 | +316.9% | Beat |
| 08 May 2019 16:00 | -0.15 | -0.05 | +64.3% | Beat |
| 27 Feb 2019 16:00 | -0.12 | -0.10 | +17.1% | Beat |
| 08 Nov 2018 16:00 | -0.12 | -0.25 | -104.7% | Miss |
| 08 Aug 2018 16:00 | -0.33 | -0.15 | +55.1% | Beat |
| 09 May 2018 16:00 | -0.65 | -0.57 | +12.0% | Beat |
| 07 Mar 2018 16:00 | -0.55 | -0.54 | +2.5% | Beat |
| 08 Nov 2017 16:00 | -0.73 | -0.45 | +38.2% | Beat |
| 09 Aug 2017 16:00 | -0.80 | -0.72 | +10.6% | Beat |
| 10 May 2017 16:00 | -1.00 | -0.79 | +20.8% | Beat |
| 09 Mar 2017 16:00 | -1.08 | -1.02 | +5.6% | Beat |
| 10 Nov 2016 16:00 | -1.11 | -1.13 | -1.4% | Miss |
| 10 Aug 2016 16:00 | -0.82 | -1.05 | -27.7% | Miss |
| 10 May 2016 16:00 | -0.49 | -0.68 | -38.1% | Miss |
| 18 Mar 2016 17:00 | -0.43 | -0.46 | -5.8% | Miss |
| 12 Nov 2015 06:00 | -0.29 | -0.46 | -58.6% | Miss |
| 12 Aug 2015 17:00 | -0.31 | -0.45 | -45.2% | Miss |
| 22 Jun 2015 17:00 | -0.16 | -0.18 | -14.4% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 780.6M | +23.6% | 62.9M | 8.1% | 1.73 | -7.0% | 327.6M |
| 2024 | 631.4M | +11.4% | 69.2M | 11.0% | 1.86 | +44.2% | 203.3M |
| 2023 | 566.8M | +22.2% | 48.2M | 8.5% | 1.29 | +274.3% | 274.3M |
| 2022 | 463.9M | — | -25M | -5.4% | -0.74 | — | 122.6M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 10 May 2024 | 33.01 | 34.00 | 30.42 | 31.50 | -16.80% | 2,253,700 | |
| 09 May 2024 | 38.31 | 38.60 | 37.60 | 37.86 | -0.53% | 364,000 | |
| 08 May 2024 | 37.25 | 38.28 | 37.22 | 38.06 | +2.04% | 317,000 | |
| 07 May 2024 | 37.04 | 37.65 | 37.00 | 37.30 | +0.76% | 199,300 | |
| 06 May 2024 | 37.51 | 37.92 | 36.88 | 37.02 | -1.31% | 304,900 | |
| 03 May 2024 | 37.80 | 38.32 | 37.29 | 37.51 | 0.00% | 300,400 | |
| 02 May 2024 | 38.16 | 38.16 | 37.18 | 37.51 | -0.71% | 312,800 | |
| 01 May 2024 | 37.12 | 38.47 | 37.03 | 37.78 | +2.30% | 369,800 | |
| 30 Apr 2024 | 36.93 | 38.18 | 36.75 | 36.93 | +0.60% | 370,500 | |
| 29 Apr 2024 | 36.51 | 37.17 | 36.51 | 36.71 | +0.80% | 219,500 | |
| 26 Apr 2024 | 35.95 | 36.57 | 35.79 | 36.42 | +1.62% | 252,800 | |
| 25 Apr 2024 | 35.37 | 36.01 | 35.05 | 35.84 | +1.01% | 338,000 | |
| 24 Apr 2024 | 35.83 | 36.02 | 35.33 | 35.48 | -1.28% | 302,800 | |
| 23 Apr 2024 | 35.00 | 36.51 | 34.92 | 35.94 | +3.45% | 618,700 | |
| 22 Apr 2024 | 34.93 | 35.31 | 34.55 | 34.74 | -0.29% | 414,700 | |
| 19 Apr 2024 | 34.65 | 35.34 | 34.24 | 34.84 | +0.20% | 325,400 | |
| 18 Apr 2024 | 35.47 | 35.47 | 34.69 | 34.77 | -1.92% | 203,900 | |
| 17 Apr 2024 | 35.47 | 35.75 | 34.76 | 35.45 | +0.14% | 256,500 | |
| 16 Apr 2024 | 35.03 | 35.81 | 34.74 | 35.40 | +0.74% | 323,800 | |
| 15 Apr 2024 | 35.67 | 35.98 | 35.12 | 35.14 | -1.60% | 366,300 | |
| 12 Apr 2024 | 36.51 | 36.51 | 35.47 | 35.71 | -1.87% | 380,400 | |
| 11 Apr 2024 | 37.97 | 37.97 | 35.72 | 36.39 | -4.21% | 462,900 | |
| 10 Apr 2024 | 38.29 | 38.89 | 37.95 | 37.99 | -2.06% | 311,400 | |
| 09 Apr 2024 | 39.37 | 39.53 | 38.41 | 38.79 | -1.60% | 204,200 | |
| 08 Apr 2024 | 39.67 | 40.02 | 38.89 | 39.42 | -1.43% | 235,200 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 07 Nov 2026 21:14
- Collegium Pharmaceutical, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 07 Nov 2026 21:04
- Collegium Pharmaceutical Inc (COLL) (Q3 2026) Earnings Call Highlights: ADHD Franchise Hits ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 21:09
- Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28 (opens in a new tab) Benzinga · 06 Nov 2026 10:21
- Collegium Pharmaceutical, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 05 Nov 2026 23:28
- Collegium (COLL) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 20:13
- Collegium Pharmaceutical Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 05 Nov 2026 15:14
- Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates (opens in a new tab) Zacks · 05 Nov 2026 13:35
- Collegium Pharmaceutical (NASDAQ:COLL) Posts Mixed Q3 as EPS Beats, Revenue Misses, and Guidance Holds (opens in a new tab) ChartMill · 05 Nov 2026 13:34
- Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars (opens in a new tab) StockStory · 05 Nov 2026 13:33
- Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics (opens in a new tab) Zacks · 05 Nov 2026 13:30
- Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $44 (opens in a new tab) Benzinga · 05 Nov 2026 13:29
- Collegium Pharmaceutical: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 05 Nov 2026 12:51
- Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance (opens in a new tab) 05 Nov 2026 12:30
- Collegium Pharmaceutical Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 05 Nov 2026 10:18
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 25.16 USD
- Market cap
- 752.3M
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 5.8 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 12.1 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 14.7 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 22.21× | Fair | 30.3× |
| P/E (forward) | 3.34× | Good | 14.94× |
| Price / book | 2.54× | Fair | 3.81× |
| Price / sales | 0.92× | Good | 3.19× |
| EV / EBITDA | 4.33× | Good | 12.63× |
| Free cash flow yield | 48.8% | Good | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 89.4% | Good | 58.6% |
| Operating margin | 24.6% | Good | 7.8% |
| Net margin | 4.7% | Weak | 2.8% |
| Return on equity | 13.4% | Fair | 5.7% |
| Return on assets | 6.3% | Fair | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 18.9% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 4.07× | Weak | 0.48× |
| Net debt / EBITDA | 2.53× | Fair | 1.58× |
| Interest cover | 2.17× | Weak | 2.76× |
| Current ratio | 1.01× | Fair | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow COLL and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.